Advertisement


Gabriel N. Hortobagyi, MD, on Breast Cancer Staging: New and Important Changes

2018 ASCO Annual Meeting

Advertisement

Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses the 8th edition of the TNM staging system, which includes prognostic stage groups based on clinical and pathologic factors combined with grade and hormone and HER2 status.



Related Videos

Gynecologic Cancers
Immunotherapy

David M. O’Malley, MD, on Ovarian Cancer: Early Results From the FORWARD II Study

David M. O’Malley, MD, of The Ohio State University College of Medicine, discusses phase Ib study findings on mirvetuximab soravtansine, a folate receptor alpha-targeting antibody-drug conjugate, in combination with bevacizumab in patients with platinum-resistant ovarian cancer (Abstract 5549).

Symptom Management

Ryan D. Nipp, MD, on Electronic Symptom Monitoring: Trial Results

Ryan D. Nipp, MD, of Massachusetts General Hospital, discusses study findings on electronic symptom monitoring vs usual care to assess whether the intervention, tested in hospitalized patients with advanced cancer, can improve symptom burden and reduce the risk of readmission (Abstract 10005).

Skin Cancer

Paolo A. Ascierto, MD, on Melanoma: Results From the COLUMBUS Trial

Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori–Fondazione Pascale, discusses phase III study findings on encorafenib plus binimetinib vs vemurafenib or encorafenib in BRAF-mutant melanoma (Abstract 9504).

Gynecologic Cancers

Ursula A. Matulonis, MD, and Daniel J. Margul, MD, PhD, on Cervical Cancer and Minimally Invasive Surgery

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Daniel J. Margul, MD, PhD, of Northwestern University, discuss the outcomes and costs of open, robotic, and laparoscopic radical hysterectomy for stage IB1 cervical cancer (Abstract 5502).

Head and Neck Cancer

Jed A. Katzel, MD, on Head and Neck Cancer: Findings on Treatment of Female Patients

Jed A. Katzel, MD, of Kaiser Permanente, discusses his team’s findings on the disparities in head and neck cancer treatment for women and the possible missed opportunities to take a more aggressive and beneficial approach (Abstract LBA6002).

Advertisement

Advertisement




Advertisement